158 related articles for article (PubMed ID: 38907875)
1. Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.
Madan V; Ortiz-López LI; Sakunchotpanit G; Chen R; Nayudu K; Nambudiri VE
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38907875
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
[No Abstract] [Full Text] [Related]
3. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors.
Cutroneo P; Ingrasciotta Y; Isgrò V; Rullo EV; Berretta M; Fiorica F; Trifirò G; Guarneri C
Dermatol Ther; 2021 Mar; 34(2):e14830. PubMed ID: 33527643
[TBL] [Abstract][Full Text] [Related]
6. Loss of epidermal Langerhans cells in psoriasiform lesions of de novo induced or worsened pre-existing psoriasis following uses of immune checkpoint inhibitors.
Kase M; Fujita Y; Ota A; Shimizu S; Itoi-Ochi S; Sano S
J Dermatol; 2022 Sep; 49(9):916-920. PubMed ID: 35545886
[TBL] [Abstract][Full Text] [Related]
7. New-Onset Psoriasis Induced by Durvalumab.
Shoukfeh R; Yassine R; Turk D; Moossavi M; Nofzinger A
Cureus; 2023 Nov; 15(11):e48453. PubMed ID: 38074037
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Nikolaou V; Sibaud V; Fattore D; Sollena P; Ortiz-Brugués A; Giacchero D; Romano MC; Riganti J; Lallas K; Peris K; Voudouri D; Lallas A; Fabbrocini G; Lazaridou E; Carrera C; Annunziata MC; Rossi E; Patri A; Rigopoulos D; Stratigos AJ; Apalla Z
J Am Acad Dermatol; 2021 May; 84(5):1310-1320. PubMed ID: 33279646
[TBL] [Abstract][Full Text] [Related]
9. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
10. Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration.
Çelik U; Aydemir EH; Engin B; Oba MÇ; Yılmaz M; Meşe ŞG
J Oncol Pharm Pract; 2021 Dec; 27(8):1853-1860. PubMed ID: 33131448
[TBL] [Abstract][Full Text] [Related]
11. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors.
Jfri A; Leung B; Said JT; Semenov Y; LeBoeuf NR
Immunother Adv; 2022; 2(1):ltac016. PubMed ID: 36196370
[TBL] [Abstract][Full Text] [Related]
14. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
Seervai RNH; Heberton M; Cho WC; Gill P; Murphy MB; Aung PP; Nagarajan P; Torres-Cabala CA; Patel AB; Ruiz-Bañobre J; Om A; Yamamoto T; Nikolaou V; Curry JL
J Cutan Pathol; 2022 May; 49(5):472-481. PubMed ID: 34888886
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Induced Psoriasis: Diagnosis, Management, and a Review of Cases.
Pach JJ; Mbonu N; Bhullar S; Cohen JM; Leventhal JS
Dermatol Clin; 2024 Jul; 42(3):481-493. PubMed ID: 38796277
[TBL] [Abstract][Full Text] [Related]
16. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
[TBL] [Abstract][Full Text] [Related]
18. A Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma.
Mullangi S; Ponnam S; Lekkala MR; Koya S
Cureus; 2021 Jun; 13(6):e15703. PubMed ID: 34290912
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Chen CH; Yu HS; Yu S
Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
[TBL] [Abstract][Full Text] [Related]
20. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.
Mital R; Otto TS; Savu A; Baumrin E; Cardones AR; Carlesimo M; Caro G; Freites-Martinez A; Hirner JP; Markova A; McLellan BN; Rossi A; Sauder MB; Seminario-Vidal L; Sibaud V; Owen DH; Dulmage BO; Chen ST; Kaffenberger BH
Int J Dermatol; 2023 Aug; 62(8):1020-1025. PubMed ID: 37203799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
